# üìù Literature Summaries ‚Äì B2554 Project

This file contains summaries of key literature relevant to inflammation resolution mechanisms in atherosclerosis, with an emphasis on genes, SPMs, and transcriptomic findings.

---

## 1. Kotlyarov & Kotlyarova, 2022 ‚Äì *Molecular Pharmacology of Inflammation Resolution in Atherosclerosis*

**Study Type:** Narrative Review  

**Focus:**  
- Imbalance between pro-inflammatory mediators and SPMs in atherosclerosis.  
- Introduces ‚Äúresolution pharmacology‚Äù as a therapeutic concept.  

**Key Genes/Enzymes:** ALOX5, ALOX15, PTGS2, ALOX5AP, CYP450, ABCA1, ABCB11  
**Receptors:** FPR2, CMKLR1, GPR32, AhR, CysLT1R  
**SPMs:** LXA4, 15-epi-LXA4, RvD1, RvD2, RvE1, PD1, PDX, MaR1, MaR2  

**Takeaway:**  
These genes and receptors are ideal for tracking resolution failure in unstable plaques using transcriptomic data.

---

## 2. Tanwar et al., 2023 ‚Äì *PARAIL Regulates Inflammation via ELAVL1*

**Study Type:** RNA-seq + Functional studies  

**Focus:**  
- lncRNA **PARAIL** suppresses inflammatory genes by retaining **ELAVL1** in the nucleus.  

**Key Genes:** PARAIL, ELAVL1, RIPK2  
**Inflammatory Targets:** IL1B, IL6, TNF, PTGS2, THBS1  

**Takeaway:**  
PARAIL‚ÄìELAVL1 is a non-lipid, transcript-stability-based resolution mechanism worth tracking in atherosclerosis datasets.

---

## 3. Hajeyah et al., 2020 ‚Äì *The Biosynthesis of Enzymatically Oxidized Lipids*

**Study Type:** Review  

**Focus:**  
- Enzymology of oxylipin/SPM biosynthesis.  

**Key Enzymes:** ALOX5, ALOX15, PTGS2, ALOX5AP, CYP4F2, AKR1B1  

**Takeaway:**  
Essential reference for interpreting resolution gene function in RNA-seq analysis.

---

## 4. Serhan et al., 2022 ‚Äì *E-series Resolvins & SPM Function*

**Study Type:** Review + Experimental validation  

**Focus:**  
- Structure, function, and roles of RvE1‚ÄìRvE4.  

**Key Enzymes/Receptors:** ALOX5, 15-LOX, COX-2, LTA4H, ChemR23, BLT1  

**Takeaway:**  
RvE4 is a newly identified potent SPM with clinical potential.

---

## 5. Engelen et al., 2022 ‚Äì *Targeting Inflammation & Resolution in Atherosclerosis*

**Study Type:** Review + Clinical trial synthesis  

**Focus:**  
- SPM-based therapy and efferocytosis enhancement in CVD.  

**Key Genes/Receptors:** FPR2, CMKLR1, MERTK, LRP1, CD47, IL1B, IL6, ELAVL1  

**Takeaway:**  
Resolution pathways like RvD1, RvE1, and efferocytosis are emerging drug targets.

---

## 6. Viola & Soehnlein, 2015 ‚Äì *Atherosclerosis as Unresolved Inflammation*

**Study Type:** Narrative Review  

**Focus:**  
- SPM reduction and efferocytosis failure as key drivers of plaque instability.  

**Mechanisms:** Macrophage polarization, oxidized LDL, chronic inflammation  

**Takeaway:**  
Restoring resolution via SPM analogs or macrophage programming is a potential strategy.

---

## 7. Fernandez et al., 2019 ‚Äì *Single-Cell Transcriptomics of Atherosclerosis*

**Study Type:** Single-cell RNA-seq  

**Focus:**  
- Cell-type specific resolution gene signatures in plaques.  

**Key Genes:** NR4A1, MERTK, TREM2, IL10, TGFB1, CD163  

**Takeaway:**  
Single-cell data identifies resolution-competent immune subsets in human lesions.

---

## 8. Mokry et al., 2023 ‚Äì *Transcriptomic Clustering of Plaques*

**Study Type:** Bulk RNA-seq re-analysis  

**Focus:**  
- Molecular subtypes of atherosclerotic plaques based on inflammation/resolution status.  

**Key Genes:** ALOX5, PTGS2, MERTK  

**Takeaway:**  
Subtyping plaques helps target resolution-deficient patient groups for analysis.

---

## 9. Fredman & Tabas, 2017 ‚Äì *Macrophage Resolution Genomics in Atherosclerosis*

**Study Type:** Review  

**Focus:**  
- Genomic regulation of macrophage trafficking and efferocytosis.  

**Key Genes/Networks:** MERTK, LRP1, ABCA1, NR4A1, KLF2, PPARŒ≥  

**Takeaway:**  
Macrophage behavior and lipid handling genes are critical in resolution failure.

---


